Biotech News

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Arbutus (ABUS)ArbutusFDA / regulatory

Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious

Related news

ABUSArbutus2026-10-22 11:30 EST

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

RHHBYRoche Holdings AG2026-11-16 06:00 EST

Roche’s Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy

RHHBYRoche Holdings AG2026-10-16 05:00 EST

FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

PHARPharming Group2026-09-11 18:00 EST

FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.

ANTXAN2 Therapeutics2026-11-02 12:00 EST

AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera

JNJJohnson & Johnson2026-10-23 11:09 EST

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse

BNTCBenitec Biopharma2026-10-05 12:00 EST

Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study

JNJJohnson & Johnson2026-09-21 14:33 EST

European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

SIGASIGA Technologies Inc2026-11-09 21:01 EST

SIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D.

ABUSArbutus2026-10-01 11:30 EST

Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Arbutus

Hepatitis B Therapeutics Arbutus Biopharma develops therapies intended to achieve a functional cure for chronic hepatitis B. Its current clinical strategy centers on suppressing viral antigen production with RNA interference. Imdusiran Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins,...

Recent company news

Stock data

Close
4.07 USD
Market cap
841.51M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States